<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Dermatol</journal-id><journal-id journal-id-type="publisher-id">IJD</journal-id><journal-title-group><journal-title>Indian Journal of Dermatology</journal-title></journal-title-group><issn pub-type="ppub">0019-5154</issn><issn pub-type="epub">1998-3611</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24249897</article-id><article-id pub-id-type="pmc">3827517</article-id><article-id pub-id-type="publisher-id">IJD-58-451</article-id><article-id pub-id-type="doi">10.4103/0019-5154.119955</article-id><article-categories><subj-group subj-group-type="heading"><subject>Therapeutic Round</subject></subj-group></article-categories><title-group><article-title>A Comparative Randomized Open Label Study to Evaluate Efficacy, Safety and Cost Effectiveness Between Topical 2% Sertaconazole and Topical 1% Butenafine in Tinea Infections of Skin</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thaker</surname><given-names>Saket J</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Mehta</surname><given-names>Dimple S</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Hiral A</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Dave</surname><given-names>Jayendra N</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Mundhava</surname><given-names>Shailesh G</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><italic>From the Department of Pharmacology and Department of Dermatology, C.U. Shah Medical College, Surendranagar, Gujarat, India</italic></aff><author-notes><corresp id="cor1"><italic><bold>Address for correspondence:</bold> Dr. Saket J. Thaker, Department of Clinical Pharmacology, 2<sup>nd</sup> Floor New M.S. Building, Seth G.S. Medical College and K.E.M.H., Parel, Mumbai - 400 012, Maharashtra, India. E-mail: <email xlink:href="saketthaker@gmail.com">saketthaker@gmail.com</email></italic></corresp></author-notes><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2013</year></pub-date><volume>58</volume><issue>6</issue><fpage>451</fpage><lpage>456</lpage><history><date date-type="received"><month>5</month><year>2012</year></date><date date-type="accepted"><month>8</month><year>2012</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Dermatology</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Dermatophytoses are the superficial fungal infections of skin, hair, and nail. Butenafine is a benzylamine group of antifungal that inhibits the biosynthesis of ergosterol by blocking squalene epoxidase. Sertaconazole is a newer imidazole antifungal which inhibits the biosynthesis of ergosterol by inhibiting 14-&#x003b1; lanosterol demethylase. The study was done to compare a newer antifungal with a relatively older one.</p></sec><sec id="st2"><title>Aim:</title><p>To compare the efficacy, safety and cost effectiveness of topical 2% sertaconazole cream and 1% butenafine in tinea infections of skin.</p></sec><sec id="st3"><title>Materials and Methods:</title><p>Patients were randomly allocated to two treatment groups. They were advised to apply the drug topically twice a day for one month on the lesions. They were followed up at an interval of 10 days. Clinical score and Global Evaluation Response were assessed at baseline and during each follow up.</p></sec><sec id="st4"><title>Results:</title><p>A total 125 patients were recruited, out of them 111 completed the whole study. Median Sign and Symptom Score of tinea on the baseline was 9 [5,9] that was reduced to 0 [0,4] by 2% sertaconazole while it was 9 [6,9] in the butenafine group on the baseline that was reduced to 0 [0,6] at the end of the treatment. 98% and 90% of the patients got complete clearance of the lesions with butenafine and sertaconazole, respectively. Treatment with butenafine was more cost effective as compared to sertaconazole.</p></sec><sec id="st5"><title>Conclusion:</title><p>1% butenafine is more efficacious, cost effective, and equally safe as compared to 2% sertaconazole in the tinea infections of skin.</p></sec></abstract><kwd-group><kwd><italic>Butenafine</italic></kwd><kwd><italic>cost effectiveness</italic></kwd><kwd><italic>efficacy</italic></kwd><kwd><italic>safety</italic></kwd><kwd><italic>sertaconazole</italic></kwd><kwd><italic>tinea infections</italic></kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>Introduction</title><boxed-text position="float"><p><bold>What was known?</bold></p><p>The imidazole antifungals are fungistatic while allylamine group agents are fungicidal. Fungicidal agents prevent relapse as compared to fungistatic agents.</p></boxed-text><p>Dermatophytoses are fungal infections caused by three genera of fungi that have the unique ability to invade and multiply within keratinized tissue (hair, skin and nails).[<xref ref-type="bibr" rid="ref1">1</xref>] Various systemic and topical antifungal agents are available for the treatment of dermatophytosis.[<xref ref-type="bibr" rid="ref2">2</xref>] Butenafine is a benzylamine which are structurally related to allylamines. It exerts antifungal activity by blocking squalene epoxidation (catalyzed by squalene epoxidase), with resultant inhibition of ergosterol synthesis.[<xref ref-type="bibr" rid="ref2">2</xref><xref ref-type="bibr" rid="ref3">3</xref>] Contact dermatitis, erythema, irritation, and itching are the adverse reactions reported with butenafine.[<xref ref-type="bibr" rid="ref3">3</xref>] Sertaconazole is an imidazole antifungal drug, which inhibits the fungal biosynthesis of ergosterol, by inhibiting the enzyme 14-&#x003b1; lanosterol demethylase.[<xref ref-type="bibr" rid="ref3">3</xref>] Sertaconazole possesses both fungistatic and fungicidal activity depending upon its concentration.[<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref5">5</xref>] It has anti- inflammatory activity also. Adverse events reported with sertaconazole are contact dermatitis, dry skin, application site reactions.[<xref ref-type="bibr" rid="ref5">5</xref>] Sertaconazole is a newer antifungal agent as compared to butanafine. No, studies are done to compare the efficacy, safety, and cost effectiveness between these two agents in tinea infections of skin.</p></sec><sec id="sec1-2"><title>Aims and Objectives</title><sec id="sec2-1"><title>Aims</title><p>To compare the efficacy, safety and cost effectiveness of topical 2% sertaconazole with topical 1% butenafine in tinea infections of skin.</p></sec><sec id="sec2-2"><title>Objectives</title><sec id="sec3-1"><title>Primary objectives</title><p>Assessment of cure rate, Assessment of effectiveness of the treatments, Evaluation of safety.</p></sec><sec id="sec3-2"><title>Secondary objectives</title><p>Comparison of relapse rate with both the treatments, To identify and find the distribution of different species of tinea.</p></sec></sec></sec><sec sec-type="materials|methods" id="sec1-3"><title>Materials and Methods</title><p>This study was registered with CTRI (Clinical Trial Registry of India) (CTRI/2012/06/002714). The study was approved by ethics committee of the teaching hospital. This was a prospective, randomized, open label, controlled, clinical study, conducted in patients attending the skin OPD of the teaching hospital, from June 2009 to January 2010. Diagnosis of tinea infections was done by the dermatologists.</p><sec id="sec2-3"><title>Inclusion criteria</title><p>(1) Patients (New cases) from skin OPD having tinea infections of skin.</p></sec><sec id="sec2-4"><title>Exclusion criteria</title><p>(1) Follow up cases (2) pregnant or lactating women, (3) patients having allergy to topical imidazole or allylamine group of antifungal used in the study.</p><p>All the patients were approached and explained about the study. Written informed consent was taken from the each patient prior to the treatment.</p><p>Patients were allocated to both the treatment group in 1:1 ratio with alternate randomization. Group A: Received topical 2% sertaconazole cream to be applied twice a day for one month. Group B: Received topical 1% butenafine cream to be applied twice a day for one month. All patients were given oral chlorpheniramine maleate (4 mg) twice a day for a month for the relief of itching. 2% sertaconazole and 1% butenafine were purchased from the pharmacy store of the hospital. After clinical diagnosis, skin scraping was collected from the site of the lesion for mycological diagnosis.</p></sec><sec id="sec2-5"><title>Microscopy [Figures <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>]</title><p>1-2 drops of 20% KOH (Potassium Hydroxide) were put on the skin scraping collected on the slide which was observed under 10x and 45x of the microscope.[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref6">6</xref>]</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Fungal eliment (hyphe) in 20% KOH</p></caption><graphic xlink:href="IJD-58-451-g001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Fungal eliment (hyphe) in 20% KOH</p></caption><graphic xlink:href="IJD-58-451-g002"/></fig></sec><sec id="sec2-6"><title>Culture [Figures <xref ref-type="fig" rid="F3">3</xref>-<xref ref-type="fig" rid="F6">6</xref>]</title><p>Skin scraping was spread on plates of Sabouraud's agar supplemented with 1% Chloramphenicol to inhibit bacterial growth. The plates were packed air tight and incubated at 32-35<sup>o</sup> C in a special incubator for 7-10 days. They were seen at an interval of 3-4 days. Plates showing no growth at the end of four weeks were labeled as culture negative.[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref6">6</xref>]</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><italic>E. Floccosum</italic> in sabauraud&#x000e6;s dextrose agar</p></caption><graphic xlink:href="IJD-58-451-g003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p><italic>T. mentagrophytes</italic> in sabauraud&#x000e6;s dextrose agar</p></caption><graphic xlink:href="IJD-58-451-g004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p><italic>T. rubrum</italic> in sabouraud&#x000e6;s dextrose agar</p></caption><graphic xlink:href="IJD-58-451-g005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><p><italic>T. verrucossum</italic> in sabouraud&#x000e6;s dextrose agar</p></caption><graphic xlink:href="IJD-58-451-g006"/></fig></sec><sec id="sec2-7"><title>Identification of species [Figures <xref ref-type="fig" rid="F7">7</xref>-<xref ref-type="fig" rid="F10">10</xref>]</title><p>Lactophenol cotton blue preparation (Sellotape) was used. These slides were seen under 10x and 45x. Species identification was done by the microbiologists on the basis of both gross as well as microscopic features. Photographs of both gross cultures and microscopic appearance of lactophenol cotton blue preparation were taken.</p><fig id="F7" position="float"><label>Figure 7</label><caption><p><italic>E. flocosum</italic> in lactophenol cotton blue preparation</p></caption><graphic xlink:href="IJD-58-451-g007"/></fig><fig id="F8" position="float"><label>Figure 8</label><caption><p><italic>T. mentagrophytes</italic> in lactophenol cotton blue preparation</p></caption><graphic xlink:href="IJD-58-451-g008"/></fig><fig id="F9" position="float"><label>Figure 9</label><caption><p><italic>T. rubrum</italic> in lactophenol cotton blue preparation</p></caption><graphic xlink:href="IJD-58-451-g009"/></fig><fig id="F10" position="float"><label>Figure 10</label><caption><p><italic>T. verrucossum</italic> in lactophenol cotton blue preparation</p></caption><graphic xlink:href="IJD-58-451-g010"/></fig><p>Patients were followed up at the interval of 10 day intervals. All the patients were followed up for 4 weeks after completion of the treatment to assess the relapse.</p><p>Outcome of the treatment was measured by two parameters:[<xref ref-type="bibr" rid="ref7">7</xref><xref ref-type="bibr" rid="ref8">8</xref>]</p><p>
<list list-type="order"><list-item><p>Clinical cure</p></list-item><list-item><p>Mycological cure.</p></list-item></list>
</p><sec id="sec3-3"><title>Clinical cure</title><p>Three parameters Erythema; Pruritus - and Scaling each categorized into - Mild-1, Moderate-2, and Severe-3 were scored at baseline and during each follow up. Maximum score was 9.</p><p>Global Evaluation Response[<xref ref-type="bibr" rid="ref6">6</xref><xref ref-type="bibr" rid="ref7">7</xref>] was assessed at each follow up which is characterized as (1) Cleared: 100% remission of the clinical signs and symptoms except for residual manifestations (2) Excellent: 90-99% improvement of clinical signs and symptoms of baseline (3) Good: 50-89% improvement of clinical signs and symptoms of baseline (4) Fair: 25-49% improvement of clinical signs and symptoms of baseline (5) Poor: &#x0003c;25% improvement of clinical signs and symptoms of baseline (6) Worse: Clinical signs deteriorated from baseline</p></sec><sec id="sec3-4"><title>Mycological cure</title><p>When patients were cured clinically, skin scraping was taken and seen microscopically and cultured. When both KOH and culture were negative, if either of both positive before treatment were declared as mycologically cured.</p></sec></sec><sec id="sec2-8"><title>Statistical analysis</title><p>nMaster 1.0 was used to calculate the sample size. Assuming the change in mean baseline sign and symptoms score with S.D. in the sertaconazole group to be 2 and the butenafine group to be 3 and estimated difference between two groups of 1 with alpha error set at the level of 5%, 50 subjects need to be recruited per arm. Considering dropout rate of 20%, total 125 subjects were recruited. Graph Pad Instat 3.0 was used for the statistical analysis. Normality of the data was checked by Kolmogorov Smirnov test. Mann Whitney test was used to compare the groups with respect to age. Fisher's exact test was used to find the difference in both the groups in terms of gender distribution as well as to assess the relapse rate. Baseline comparison of sign and symptom score between the groups was done by Mann Whitney Test. Total score of erythema, pruritus, and scaling before and after treatment was compared by Wilcoxon matched pairs signed rank test. Chi square test was used to compare global evaluation score at each follow up. <italic>P</italic> &#x0003c; 0.05 was considered as significant in all the statistical analysis.</p></sec><sec id="sec2-9"><title>Cost effectiveness</title><p>Cost effectiveness was calculated on the basis of total cost of medicines (topical agents plus antihistamines). Total amount of topical agents required was calculated by calculating FTU (finger tip units) (One finger tip unit is equal to 0.5 g. of topical agent, provided the lumen of the tube has diameter of 5 mm). Amount of topical agent needed was calculated by averaging requirement for different sites.[<xref ref-type="bibr" rid="ref10">10</xref>] Cost of the topical agents was calculated by averaging the costs of all marketed preparations. Cost of the treatment was calculated accordingly for each follow up. Incremental cost (&#x00394;C) = Cost of the new treatment &#x02013; cost of the old treatment. Incremental effectiveness (&#x00394;E) = efficacy of the new treatment- efficacy of old treatment.[<xref ref-type="bibr" rid="ref9">9</xref>]</p></sec></sec><sec sec-type="results" id="sec1-4"><title>Results</title><p>A total 125 patients were enrolled for the study out of whom 5 patients from the sertaconazole group (Group A) and 9 patients from the butenafine group (group B) were lost to follow up. Finally, 111 patients completed the study.</p><p>Demographic characteristics</p><p>Median age in group A was 34[10,76] and in group B it was 35.(8,76) There was no difference between both the groups in age distribution (Mann&#x02013;Whitney test; <italic>P</italic> value 0.53). There was a statistically significant difference between the groups in gender distribution (Fischer's exact test <italic>P</italic> value- 0.015).</p><p>Distribution of patients and species of tinea</p><p>Tinea corporis and cruris mixed infections was the most common diagnosis (27.92%) followed by tinea corporis (26.13%) [<xref ref-type="table" rid="T1">Table 1</xref>]. Most of the patients (86.48%) were suffering from severe tinea infection at the time of presentation. <italic>T. mentagrophytes</italic> (42.62%) was the most common species found followed by <italic>T. rubrum</italic> (24.59%) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Distribution of patients according to diagnosis</p></caption><graphic xlink:href="IJD-58-451-g011"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Distribution of tinea species between groups<sup>#*</sup></p></caption><graphic xlink:href="IJD-58-451-g012"/></table-wrap><p>Efficacy (Sign and symptom score)</p><p>Bothe groups were matched with respect to baseline sign and symptom score (Mann&#x02013;Whitney test; <italic>P</italic> value: 0.068). Median Sign and Symptom Score of tinea at the baseline was 9 [5, 9] that was reduced to 0 [0, 4] by 2% sertaconazole while it was 9 [6, 9] in the butenafine group at the baseline that was reduced to 0 [0, 6] at the end of the treatment. Both were statistically significant. (Wilcoxon matched pair test, <italic>P</italic> &#x0003c; 0.001).</p><p>Efficacy (Global Evaluation Response)</p><p>On comparison of Global Evaluation Response at each follow up between both the groups by the Chi-square test [<xref ref-type="table" rid="T3">Table 3</xref>], there was a significant association between both the treatments at the first follow up (<italic>P</italic> 0.004. None of the treatments showed significant association at the second and third follow ups (<italic>P</italic> &#x0003e; 0.01).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Global evaluation response at each follow up</p></caption><graphic xlink:href="IJD-58-451-g013"/></table-wrap><p>Efficacy (Mycological cure) [<xref ref-type="table" rid="T4">Table 4</xref>]</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Relationship between KOH and culture</p></caption><graphic xlink:href="IJD-58-451-g014"/></table-wrap><p>90% of the patients with sertaconazole and 97% of the patients with butenafine achieved mycological cure. There was a significant difference in mycological cure in both the groups individually (McNemar's test <italic>P</italic>=0.0001 for both the groups). But there was no difference between both the groups. Chi square test, <italic>P</italic>=0.29].</p><sec id="sec2-10"><title>Safety of the therapy</title><p>No patient from either group complained of any application site or systemic adverse events during the course of treatment.</p></sec><sec id="sec2-11"><title>Relapse</title><p>No relapse was seen in the butenafine treatment group while three patients cured with sertaconazole relapsed at the end of 4 weeks surveillance period. There was no difference between both the groups in terms of relapse rate. (Fischer's exact test; <italic>P</italic> value 0.2482)</p></sec><sec id="sec2-12"><title>Cost effectiveness</title><p>Total cost of therapy was more with sertaconazole as compared to butenafine treatment. The total cost of the treatment with 1% butenafine was 316.21, while it was 978.56 with 2% sertaconazole. Incremental cost (&#x00394;C) was 662.35. Incremental effectiveness (&#x00394;E) was 8%.</p></sec></sec><sec sec-type="discussion" id="sec1-5"><title>Discussion</title><p>Dermatophytoses (tinea) infections are one of the most common fungal infections of skin.[<xref ref-type="bibr" rid="ref11">11</xref>] Results of the present study show that both butenafine and sertaconazole significantly reduced base line sign and symptom score. But global evaluation response showed more clearance of the lesion with butenafine at the end of treatment, which was also beneficial in preventing the relapse. Both the agents were found safe but butenafine was more cost-effective as compared to sertaconazole.</p><p>In the present study, most common age group infected with tinea infections was 11-30 years. The male female ratio was 3.44:1. Tinea cruris and corporis mixed infection (27.93%) was the most common diagnosis. Sen <italic>et al</italic>.[<xref ref-type="bibr" rid="ref12">12</xref>] have reported male: female ratio 2.85: 1. The most common age group in their study was 21-30 years (44%) and the most common type of lesion reported by them was tinea corporis (48%). <italic>T. mentagrophyte</italic> (42.62%) was the most common species found in the present study followed by <italic>T. rubrum</italic> (24.59%) which contradicts a study by Kannan <italic>et al</italic>. who have found <italic>T. rubrum</italic> (70.83%) to be the most common isolate followed by <italic>T. mentagrophytes</italic> (16.7%).[<xref ref-type="bibr" rid="ref13">13</xref>]</p><p>Our study shows that 90% of the patients were completely cleared of the lesion clinically at the end of treatment with sertaconazole. Mycological cure was achieved in 90% of the patients. A study by Sharma <italic>et al</italic>., has shown that sertaconazole produced 62.3% clearance at the end of 2 weeks.[<xref ref-type="bibr" rid="ref14">14</xref>] In the study by Alomar <italic>et al</italic>., 95.6% clinical cure rate was seen at the end of treatment with sertaconazole[<xref ref-type="bibr" rid="ref15">15</xref>] This study demonstrated that 62.74% of the patients were completely cleared with the lesion clinically at the end of 2<sup>nd</sup> follow up (20 days) and 98% at 3<sup>rd</sup> follow up (30 days) with topical 1% butenafine cream. 97% of the patients achieved mycological cure at the end of treatment. Tschen <italic>et al</italic>. have reported that 40% of the patients showing mycological cure after 1<sup>st</sup> week and 88% of the patients after 4 weeks with 1% butenafine cream.[<xref ref-type="bibr" rid="ref16">16</xref>] The present study reported that no patient complained of any administration site or systemic adverse events during treatment with both the agents. Side effects reported with butenafine in the study by Rammam <italic>et al</italic>. were burning (two patients), pruritus (two patients), striae (one patient), and erythema with atropy (one patient) which were mild in intensity.[<xref ref-type="bibr" rid="ref17">17</xref>] Sharma <italic>et al</italic>. have reported five patients in the sertaconazole group and nine in the miconazole group developing mild to moderate adverse events.[<xref ref-type="bibr" rid="ref14">14</xref>] The present study shows that no patient treated with butenafine relapsed while three patients relapsed from sertaconazole treatment. However, there was no statistically significant difference between both the groups in relapse rate (<italic>P</italic> &#x0003e; 0.05). Lesher Jr <italic>et al</italic>. have concluded that as butenafine provided residual protection for 4 weeks, no relapse was seen.[<xref ref-type="bibr" rid="ref18">18</xref>] Cost-effective analysis of the present study showed treatment with butenafine cheaper as compared to sertaconazole. Results of this study are comparable to other studies however some observer bias may have occurred unintentionally.</p></sec><sec sec-type="conclusion" id="sec1-6"><title>Conclusion</title><p>1% butenafine is more efficacious, cost effective, and equally safe as compared to 2% sertaconazole in tinea infection of skin. It also provides residual protection which may prevent the relapse. Fungicidal agents should be preferred over fungistatic agents in the treatment of superficial fungal infections (tinea) to prevent the relapse. Cost should also be considered as a factor in the choice of an antifungal.</p><boxed-text position="float"><p><bold>What is new?</bold></p><p>Butenafine is more efficacious, safe as well as cost effective as compared to a relatively newer imidazole antifungal, sertaconazole in tinea infections of skin.</p></boxed-text></sec></body><back><ack><title>Acknowledgement</title><p>We are thankful to the Dean of the institute for allowing us to carry out the study in the hospital. We are also thankful to the Department of Microbiology for their cooperation. We are grateful to all the participants, who participated in the study.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> Nil.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sobera</surname><given-names>JO</given-names></name><name><surname>Elewski</surname><given-names>BE</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Sobera</surname><given-names>JO</given-names></name><name><surname>Elewski</surname><given-names>BE</given-names></name></person-group><article-title>Fungal diseases</article-title><source>Dermatology</source><year>2008</year><edition>2nd ed</edition><publisher-loc>USA</publisher-loc><publisher-name>Mosby Elsevier</publisher-name><fpage>1135</fpage><lpage>63</lpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tripahi</surname><given-names>KD</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Tripathi</surname><given-names>KD</given-names></name></person-group><article-title>Antifungal drugs</article-title><source>Essentials of Medical Pharmacology</source><year>2008</year><edition>6th Ed</edition><publisher-loc>New Delhi</publisher-loc><publisher-name>Jaypee Brothers</publisher-name><fpage>757</fpage><lpage>66</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brunton</surname><given-names>LS</given-names></name><name><surname>Lazo</surname><given-names>JS</given-names></name><name><surname>Parker</surname><given-names>KL</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Brunton</surname><given-names>LS</given-names></name><name><surname>Lazo</surname><given-names>JS</given-names></name><name><surname>Parker</surname><given-names>KL</given-names></name></person-group><article-title>Antifungal Drugs</article-title><source>Goodman and Gilman's the pharmacological basis of therapeutics</source><year>2008</year><edition>11th ed</edition><publisher-loc>USA</publisher-loc><publisher-name>McGraw-Hill Publication</publisher-name><fpage>1225</fpage><lpage>42</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrillo-Munoz</surname><given-names>JA</given-names></name><name><surname>Cristina</surname><given-names>T</given-names></name><name><surname>C&#x000e1;rdenes</surname><given-names>DC</given-names></name><name><surname>Estivill</surname><given-names>D</given-names></name><name><surname>Giusiano</surname><given-names>G</given-names></name></person-group><article-title>Sertaconazole nitrate shows fungicidal and fungistatic activities against <italic>Trichophyton rubrum, Trichophyton mentagrophytes</italic>, and <italic>Epidermophyton floccosum</italic>, causative agents of tinea pedis</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><fpage>4420</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">21746955</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croxtall</surname><given-names>JD</given-names></name><name><surname>Plosker</surname><given-names>GL</given-names></name></person-group><article-title>Sertaconazole: A review of its use in the management of superficial mycoses in dermatology and gynecology</article-title><source>Drugs</source><year>2009</year><volume>69</volume><fpage>339</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">19275277</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Heffernan</surname><given-names>MP</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Heffernan</surname><given-names>MP</given-names></name></person-group><article-title>Superficial Fungal Infection: Dermatophytosis, Onychomycosis, Tinea nigra, Piedra</article-title><source>Dermatology in General Medicine</source><year>2003</year><volume>2</volume><edition>6th ed</edition><publisher-loc>USA</publisher-loc><publisher-name>McGraw Hill Inc</publisher-name><fpage>1989</fpage><lpage>2001</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeely</surname><given-names>W</given-names></name><name><surname>Spencer</surname><given-names>CM</given-names></name></person-group><article-title>Butenafine</article-title><source>Drugs</source><year>1998</year><volume>55</volume><fpage>405</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">9530545</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jerajani</surname><given-names>HR</given-names></name><name><surname>Amladi</surname><given-names>ST</given-names></name><name><surname>Bongale</surname><given-names>R</given-names></name><name><surname>Adepu</surname><given-names>V</given-names></name><name><surname>Tendolkar</surname><given-names>UM</given-names></name><name><surname>Sentamilselvi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Evaluation of clinical efficacy and safety of once daily topical administration of 1% oxiconazole cream and lotion in dermatophytosis: An open label, non comparative multicentre study</article-title><source>Indian J Dermatol Venereol Leprol</source><year>2000</year><volume>66</volume><fpage>188</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">20877072</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitjan</surname><given-names>DF</given-names></name><name><surname>Moskowitz</surname><given-names>AJ</given-names></name><name><surname>Whang</surname><given-names>W</given-names></name></person-group><article-title>Bayesian estimation of cost effectiveness ratios from clinical trials</article-title><source>Health Econ</source><year>1999</year><volume>8</volume><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">10348414</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>CC</given-names></name><name><surname>Finlay</surname><given-names>AY</given-names></name></person-group><article-title>The fingertip unit: A new practical measure</article-title><source>Cli Exp Dermatol</source><year>1991</year><volume>16</volume><fpage>444</fpage><lpage>7</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chander</surname><given-names>J</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Chander</surname><given-names>J</given-names></name></person-group><article-title>Dermatophytosis</article-title><source>Textbook of medical mycology</source><year>2009</year><edition>3rd ed</edition><publisher-loc>New Delhi</publisher-loc><publisher-name>Mehta Publishers</publisher-name><fpage>122</fpage><lpage>46</lpage></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>SS</given-names></name><name><surname>Rasul</surname><given-names>ES</given-names></name></person-group><article-title>Dermatophytosis in Assam</article-title><source>Indian J Med Microbiol</source><year>2006</year><volume>24</volume><fpage>77</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16505568</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kannan</surname><given-names>P</given-names></name><name><surname>Janaki</surname><given-names>C</given-names></name><name><surname>Selvi</surname><given-names>GS</given-names></name></person-group><article-title>Prevalence of dermatophytes and other fungal agents isolated from clinical samples</article-title><source>Indian J Med Microbiol</source><year>2006</year><volume>24</volume><fpage>212</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16912443</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Saple</surname><given-names>DG</given-names></name><name><surname>Surjushe</surname><given-names>A</given-names></name><name><surname>Rao</surname><given-names>GR</given-names></name><name><surname>Kura</surname><given-names>M</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis</article-title><source>Mycoses</source><year>2011</year><volume>54</volume><fpage>217</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">19925567</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alomar</surname><given-names>C</given-names></name><name><surname>Bassas</surname><given-names>S</given-names></name><name><surname>Casas</surname><given-names>M</given-names></name><name><surname>Crespo</surname><given-names>V</given-names></name><name><surname>Ferr&#x000e1;ndiz</surname><given-names>C</given-names></name><name><surname>Fonseca</surname><given-names>E</given-names></name><etal/></person-group><article-title>Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering From cutaneous mycoses</article-title><source>Arzneimittelforschung</source><year>1992</year><volume>42</volume><fpage>767</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">1627204</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tschen</surname><given-names>E</given-names></name><name><surname>Elewski</surname><given-names>B</given-names></name><name><surname>Gorsulowsky</surname><given-names>DC</given-names></name><name><surname>Pariser</surname><given-names>DM</given-names></name></person-group><article-title>Treatment of interdigital tinea pedis with a 4-week once daily regimen of butenafine hydrochloride 1% cream</article-title><source>J Am Acad Dermatol</source><year>1997</year><volume>36</volume><fpage>S9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">9039199</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramam</surname><given-names>M</given-names></name><name><surname>Prasad</surname><given-names>HR</given-names></name><name><surname>Manchanda</surname><given-names>Y</given-names></name><name><surname>Khaitan</surname><given-names>BK</given-names></name><name><surname>Banerjee</surname><given-names>U</given-names></name><name><surname>Mukhopadhyaya</surname><given-names>A</given-names></name><etal/></person-group><article-title>Randomized controlled trial of topical butenafine in tinea cruris and tinea corporis</article-title><source>Indian J Dermatol Venereol Leprol</source><year>2003</year><volume>69</volume><fpage>154</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17642865</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesher</surname><given-names>JL</given-names><suffix>Jr</suffix></name><name><surname>Babel</surname><given-names>DE</given-names></name><name><surname>Stewart</surname><given-names>DM</given-names></name><name><surname>Jones</surname><given-names>TM</given-names></name><name><surname>Kaminester</surname><given-names>L</given-names></name><name><surname>Goldman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Butenafine 1% cream in the treatment of tinea cruris: A multicentre, vehicle- controlled, double- blind trial</article-title><source>J Am Acad Dermatol</source><year>1997</year><volume>36</volume><fpage>S20</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9039201</pub-id></element-citation></ref></ref-list></back></article>